Israel News App
ESMO 2025: CELC-G-201: Phase 1/2 Study of Gedatolisib in Combination with Darolutamide in mCRPC – UroToday
Written by
admin
in
6. Business
ESMO 2025: CELC-G-201: Phase 1/2 Study of Gedatolisib in Combination with Darolutamide in mCRPC
UroToday
Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic…
Continue Reading